Asceneuron Expands Scientific Advisory Board with World Leading Experts in Neurodegenerative Diseases

Significant appointments of industry and academic experts to support Phase II development of ASN51 in Alzheimer’s disease LAUSANNE, Switzerland and SAN FRANCISCO, March 6, 2024 /PRNewswire/ — Asceneuron SA, a clinical stage biotech company dedicated to targeting the root causes of…

Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks